More GlaxoSmithKline and Unilever excitement awaits…and then onto Taylor Wimpey
By Chris Bailey | Monday 17 January 2022
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Of course I am excited to see GlaxoSmithKline (GSK) shares up nicely today. No surprise, akin to my comments here yesterday, that it has formally told Unilever (ULVR) where to go. Suffice to say there is going to a load of full year number updates from the two names on 9th February (GSK) and 10th February (Unilever), but today’s additional announcement by the former of ‘detailed financial information and future growth ambitions for the new Consumer Healthcare business at a virtual Capital Markets Day for investors and analysts on Monday 28th February 2022’, is really going to be worth a listen to. As noted in my update yesterday I am holding onto my GSK shares. Let’s talk about something else and I see Taylor Wimpey (TW.) is out with its ‘trading statement for the year ended 31 December 2021’ today.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.